Cidara Therapeutics Inc (CDTX) — Cash Flow Quality Index
Latest as of March 2023:
-3.62x
Cidara Therapeutics Inc (CDTX) has a Cash Flow Quality Index of -3.62x as of March 2023. Operating cash flow of $-10.90 Million is below net income of $3.01 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore how much of Cidara Therapeutics Inc's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
-3.62x
Operating CF / Net Income
Operating Cash Flow
$-10.90 Million
USD
Net Income
$3.01 Million
USD
Data as of
Mar 2023
Most recent filing
Annual Cash Flow Quality Index for Cidara Therapeutics Inc (None–None)
Year-by-year earnings quality comparison for Cidara Therapeutics Inc. For live market cap and the full company financial profile, see Cidara Therapeutics Inc stock valuation.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.